Hillhurst’s proprietary GLASS platform enables novel uses of therapeutic gases that, up until now, have been limited by inhaled delivery. We’ve developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pai... Read more